The present study represents a replication and extension of the original Response Bias Scale (RBS) validation study. In addition to examining the relationship between the Test of Memory Malingering (TOMM), RBS, and several other well-researched Minnesota Multiphasic Personality Inventory 2 (MMPI-2) validity scales (i.e., F, Fb, Fp, and the Fake Bad Scale), the present study also included the recently developed Infrequency Post-Traumatic Stress Disorder Scale and the Henry-Heilbronner Index (HHI) of the MMPI-2. Findings from this retrospective data analysis (N = 46) demonstrated the superiority of the RBS, and to a certain extent the HHI, over other MMPI-2 validity scales in predicting TOMM failure within the outpatient Veterans Affairs population. Results of the current study confirm the clinical utility of the RBS and suggest that, particularly if the MMPI-2 is an existing part of the neuropsychological assessment, examination of RBS scores is an efficient means of detecting negative response bias. Published by Elsevier Ltd on behalf of National Academy of Neuropsychology.
Introduction
Few studies have examined the relationship between Minnesota Multiphasic Personality Inventory 2 (MMPI-2; Butcher et al., 2001 ) validity scales and performance on cognitive symptom validity tests. One early study (McCaffrey, O'Bryant, Ashendorf, & Fisher, 2003) found that the traditional MMPI-2 validity scales (VRIN, TRIN, L, F, K, Fb) did not positively correlate with any trial on the Test of Memory Malingering (TOMM; Tombaugh, 1996) or the Rey-15-Item Test (Rey-15; Rey, 1964) . Recognizing that many of these scales were originally designed to detect psychiatric malingering and were not particularly well-suited for detecting invalid performance on neuropsychological tests, Gervais, Ben-Porath, Wygant, and Green (2007) developed the Response Bias Scale (RBS), which is the only MMPI-2 scale developed specifically to detect negative response bias on cognitive testing.
RBS
The RBS (Gervais et al., 2007) consists of 28 MMPI-2 items that, in a sample of 1212 non-head-injury disability claimants, were shown to discriminate between persons who passed or failed one of several symptom validity tests, including the Word Memory Test (WMT; Green, 2003; Green & Astner, 1995; Green, Allen, & Astner, 1996) , the Computerized Assessment of Response Bias (CARB; Allen, Conder, Green, & Cox, 1997) , and/or the TOMM. Initial testing by the scale developers showed that the RBS consistently outperformed other MMPI-2 validity scales, including F, Fp, and the Fake Bad Scale (FBS; Lees-Haley, English, & Glenn, 1991) , in its ability to detect poor performance on symptom validity tests.
Three recent investigations lend further support to the demonstrated clinical utility of RBS. Nelson, Sweet, and Heilbronner (2007) showed that, of many MMPI-2 validity scales examined (e.g., L, F, K, Fb, Fp, and FBS), RBS yielded the largest effect size for differences between a group of study participants with secondary gain (N = 157) and a group with no secondary gain (N = 54). In addition, Larrabee (2008) found that, aside from RBS, FBS, and FBS-r (30-item form of the FBS to appear on the MMPI-2 Restructured Form; Ben-Porath & Tellegen, 2008) , none of the other MMPI-2 validity scales examined added meaningfully to prediction of group membership in a sample of 54 non-malingering clinical patients and 41 malingering personal injury litigants who failed at least one symptom validity test. Other MMPI-2 validity tests examined by Larrabee included, but were not limited to, F, Fp, the Infrequency Post-Traumatic Stress Disorder scale (Fptsd; Elhai et al., 2002) , and the Henry-Heilbronner Index (HHI; Henry, Heilbronner, Mittenberg, & Enders, 2006) . Another recent study provided additional support for the RBS, finding it to be a better predictor of subjective memory complaints than the F, Fb, Fp, and FBS (Gervais, Ben-Porath, Wygant, and Green, 2008) . In the latter study, higher RBS scores were associated with more subjective memory complaints but not with objective memory test scores in a sample of 1187 predominantly non-head-injury disability-related referrals, suggesting that RBS scores are associated with over-reporting.
The aim of the present study was to confirm the validity of the RBS by replicating a portion of the original RBS validation study conducted by its developers, Gervais and colleagues (2007) . As in the original study, the current study employed a retrospective chart review of clinical patients who completed both the TOMM and the MMPI-2. A primary goal of this research was to investigate whether or not the observed relationships between the TOMM and the RBS would be upheld within a VA medical center outpatient clinical sample. The present study also extended that of the original investigation by not only looking at the relationship between the TOMM and RBS, F, Fb, Fp, and FBS of the MMPI-2, but also the recently developed Fptsd (Elhai et al., 2002) and HHI (Henry et al., 2006) validity scales of the MMPI-2. It was hypothesized that, of all validity scales included, the RBS would be the scale that demonstrated the largest difference between groups of individuals who passed the TOMM versus those who failed it. In addition, it was hypothesized that, as in the original study, the RBS would incrementally contribute to each validity scale in predicting TOMM performance (pass versus fail), while the reverse would not hold true. Specifically, it was anticipated that, in a regression model, the addition of RBS to each of the other validity scales would result in a significant improvement in the ability of each scale to predict TOMM scores, while the addition of each validity scale to RBS would not result in a significant change in the accuracy of RBS in predicting TOMM performance. Prior to proceeding to a more detailed discussion of the methods used in the current study, a brief discussion of the development and validation of each of the aforementioned validity scales is presented.
F, Fb, Fp, Fptsd, and HHI
The Infrequency (F) scale is one of the four original scales developed by the authors of the MMPI (Hathaway and McKinley, 1951) to detect deviant test-taking attitudes (for review, see Graham, 1990) . F scale items (60 total) were selected by identifying statements that were endorsed by fewer than 10% of the original Minnesota normal group. Endorsement of a large number of these responses calls into question the extent to which a respondent complied with test instructions. Unlike the F scale items, all of which appear before item 362, the Infrequency-Back (Fb) items appear later in the booklet, all after item 280, and were included to detect deviant responding in the latter part of the test. The Fb scale was originally developed for the experimental booklet used in the normative data collection for the MMPI-2 (Butcher, Dahlstrom, Graham, Tellegan, & Kaemmer, 1989) . Like the F scale, the 40-item Fb scale is composed of items that were endorsed less than 10% of the time by normal individuals in the sample.
The Infrequency-Psychopathology Scale, Fp, was developed by Arbisi and Ben-Porath (1995) by selecting a set of 27 MMPI-2 items answered infrequently by both psychiatric inpatients and the MMPI-2 normative sample. It was developed to improve upon the earlier MMPI-2 validity scales, specifically F and Fb. F and Fb tend to be extremely elevated in inpatient samples, at least in part because they contain items that, if endorsed, reflect experiences not atypical of persons with acute psychiatric illness (e.g., experiencing nightmares). On the basis of their validation study, the scale developers suggested that the Fp scale be used as an adjunct to the interpretation of F and Fb, as it is far less susceptible to severe psychopathology and elevations on it are more reflective of symptom exaggeration.
The Fake Bad Scale (FBS) was developed by Lees-Haley and colleagues (1991) . It was designed to assist in the identification of invalid symptom presentation in the context of litigation. Empirical and post hoc rational analyses were used to select 43 items that reflected exaggeration of post-injury emotional distress and minimization of preinjury personality problems (Greiffenstein, Fox, & Lees-Haley, 2007) . A recent meta-analysis (N = 3663) found a large grand effect size for FBS (.96) and suggested that FBS performed as well as, if not superior to, other validity scales (including F, Fb, and Fp, discussed above) in distinguishing between groups of individuals who were likely over-reporting symptoms versus those who were not (Nelson, Sweet, & Demakis, 2006) .
The Infrequency Post-traumatic Stress Disorder Scale was developed by Elhai et al. (2002) in an attempt to create an over-reporting scale that was less easily influenced by genuine psychopathology and distress among survivors of traumatic stress than the then existing MMPI-2 validity scales. The 32 Fptsd items were selected based on their infrequent endorsement by 940 male combat veterans. Using a sample of 323 post-traumatic stress disorder(PTSD)-diagnosed combat veterans and 85 student PTSD simulators, the test developers demonstrated in the initial validation study that the Fptsd scale was better at discriminating simulated from genuine PTSD than previously established MMPI-2 validity and over-reporting scales (i.e., F, Fb, and Fp) and appeared to be less influenced by psychopathology and distress.
The Henry-Heilbronner Index (HHI) was developed by Henry et al. (2006) . It is a 15-item scale representing a "pseudosomatic factor" that was derived empirically from both the 43-item FBS and the 17-item Shaw and Mathews' Pseudoneurologic Scale (PNS; Shaw & Mathews, 1965) . In their initial validation study, the scale developers showed that the HHI was superior to FBS and PNS in the identification of symptom exaggeration in personal injury litigants and disability claimants (N = 45) compared to non-litigating head-injured controls (N = 74).
Method

Participants
Data were collected from the files of 46 outpatients who were referred to the lead author (K.W.) for neuropsychological testing within a VA Medical Center. Referral sources included the Psychiatry Ambulatory Care Clinic, primary medical clinics and the neurology clinic. No patients were diagnosed with mental retardation. Consecutive referrals were reviewed for cases that were administered both the TOMM and MMPI-2 as part of the clinical neuropsychological evaluation.
Consistent with current practice recommendations (Bush et al., 2005) and assessment guidelines (Slick, Sherman, & Iverson, 1999) , symptom validity was clinically evaluated in these patients with consideration to evidence provided by the referral context, clinical interview, behavioral observations during test administration, and performance on measures of examinee effort. Not all patients seen by K.W. are routinely administered tests of effort; however, reasons for administering effort testing in these cases were often multi-factorial and included self-reported cognitive deficits in a relatively young person (i.e., under the age of 65) who was free of major medical or neurological illness that produced symptoms obvious to the observer; the observation of multiple requests for compensation and pension evaluations in the patient's medical record; referring diagnosis of mild traumatic brain injury, somatization disorder, or electrical injury; observation of inconsistent self-reports concerning illness or injury in the patient's medical record; and/or suspicions regarding symptom exaggeration as noted by other clinicians.
It should be noted that, in the present study, all patients were primarily referred for neuropsychological evaluation to assess the potential presence of cognitive dysfunction, not primarily to assess for the presence of psychiatric disorder. At the time of this study, participants medical records were retrospectively reviewed and they were categorized into groups according to the primary reason that malingering was suspected (Table 1) . Sixteen patients were referred with symptoms of traumatic brain injury; judging by their self-reports, 12 of these patients' reported brain injuries would Table 1 Reason for suspicion of malingering and other diagnostic information.
Primary reason for suspicion of malingering n (%) of total sample have fallen within the mild range. Most patients, 27 (58.7%), were suspected of potential malingering because they were under the age of 65 and, even though they may have had a neurological diagnosis associated with potential brain dysfunction, they had no signs of neurologic dysfunction that were obvious to the observer. The majority of these patients, 15/27 (55.6%) had both neurologic and psychiatric diagnoses. These diagnoses are listed in Table 1 . As this study was retrospective in nature, it was not possible to precisely determine additional information (i.e., information from another clinician) or other aspects of the patient's presentation (i.e., mention of disability application) that may have led to the suspicion of malingering in each case. In terms of patient demographics, age of participants ranged from 29 to 62 years old, with a mean age of 47.67 years (SD = 9.21). Highest year of education completed by participants ranged from 7 to 18, with a mean level of 12.15 years (SD = 2.01). In terms of gender, 42 (91.3%) participants were male and 4 (8.7%) were female. Thirty-nine of 46 participants (84.8%) were Caucasian, 6 participants (13.0%) were African-American, and 1 participant (2.2%) was Hispanic.
Measures and procedures
The TOMM (Tombaugh, 1996) was administered according to standardized instructions by a testing technician in concert with other selected neuropsychological tests. The TOMM has been validated using numerous populations, including neurological patients, geriatrics inviduals, college student normal controls and simulators, persons simulating traumatic brain inury, actual brain injury litigants, and persons with depression (Ashendorf, Constantinou, & McCaffrey, 2004; Rees, Tombaugh, Gansler, & Moczynski, 1998; Tombaugh, 1997) . Scores less than the specified cut-offs on any trial of the TOMM raise doubt about the validity of the test-taker's performance. The TOMM is often perceived as being a harder task than it actually is; thus, individuals motivated to exaggerate impairments often perform worse than normative data predict. In the present study, patients were considered to have failed the TOMM if they performed less than chance on Trial 1 or below the cut-off listed in the test manual on either Trial 2 or the Retention Trial. All patients in the current study to whom the neuropsychologist gave a final diagnosis that included a cognitive component (e.g., dementia, post-concussion syndrome, traumatic brain injury, cognitive disorder not otherwise specified) passed the TOMM (n = 12).
The MMPI-2 (Butcher et al., 2001 ) is commonly cited as the most widely used personality test in the world (Graham, 2005) . It is employed in a variety of settings, including in mental health centers, medical centers, correctional programs, and in legal proceedings. In addition, as noted by Graham (2005) , it is increasingly being used as a screening tool for applicants desiring jobs that involve public trust and safety. All participants in the current study completed all 567 True/False items included in the measure. Validity scales used in the current analysis included those that are a standard part of the scoring software for the MMPI-2 within VA Medical Centers (F, Fb, and Fp) and those that are more recently developed and require hand scoring (Fptsd, FBS, HHI, and RBS). On the MMPI-2, no patients demonstrated TRIN > 80 or VRIN scores > 100, suggesting that patients were neither responding randomly nor were they demonstrating an acquiescent or nay-saying response style.
Statistical analyses
Except where indicated, statistical analyses were calculated using SPSS, Version 10.1 (SPSS, Chicago, IL). Initial analyses consisted of conducting independent t-tests to compare group differences in MMPI-2 validity scale scores (RBS, F, Fb, Fp, FBS, Fptsd, and HHI) among persons either failing or passing the TOMM. Alpha was set at .05 for this and all other analyses. Cohen's d effect sizes, along with 95% confidence intervals (CIs) for these group differences were calculated using a computerized program provided by Devilly (2004) . The aforementioned analyses all focused on a dichotomous distinction between groups (i.e., TOMM pass or fail). Given the additional variability inherent in continuous TOMM scores, an alternative view of the relationship between the TOMM and the MMPI-2 validity scales was created by computing two-tailed Pearson correlations between all trials on the TOMM and the various MMPI-2 validity scales.
Following the methodology of Arbisi and Ben-Porath (1995) and Gervais et al. (2007) , linear regression analyses were conducted to evaluate the incremental validity of the RBS compared to F, Fb, Fp, FBS, Fptsd, and HHI in discriminating persons who failed the TOMM from those whose passed it. For each analysis, either the F, Fb, Fp, FBS, Fptsd, or HHI raw score was entered in the first block and the RBS raw score in the second block. The F (change) statistic was used to evaluate whether or not the RBS contributed incrementally to the prediction of group membership. In the second analysis, the order of entry was reversed, with RBS entered in the first block and F, Fb, Fp, FBS, Fptsd, or HHI entered in the second block. In these analyses, the usefulness of each MMPI-2 scale in incrementally contributing to RBS in predicting TOMM performance was evaluated by looking at the significance of the F (change) statistic.
A receiver operating characteristic (ROC) curve analysis was used to evaluate the usefulness of varying RBS cut-offs in predicting TOMM failure. As part of the ROC analysis, the sensitivity and specificity of the RBS at various cut-offs was examined. Sensitivity has been defined as the proportion of persons with condition X that will be identified as such by the test (true positives; Elwood, 1993) . In the present study, sensitivity refers to the proportion of individuals who were demonstrating negative response bias (as evidenced by TOMM failure) who were identified as such by their RBS score. Specificity, on the other hand, refers to the proportion of persons without condition X who are identified as such by the test (true negatives; Elwood, 1993) . In the present study, specificity refers to the proportion of individuals who were not demonstrating negative response bias (as evidenced by passing the TOMM) who were identified as such by their RBS score.
Following the ROC analysis, positive and negative predictive values were calculated. As explained by O'Bryant and Lucas (2006), positive predictive value (PPV) refers to the likelihood that an individual has condition X (i.e., negative response bias as evidenced by TOMM failure) given positive findings on test Y (i.e., meets or exceeds RBS cut-off score) (Glaros & Kline, 1988; McCaffrey, Palav, O'Bryant, & Labarge, 2002) . Negative predictive value (NPV) is defined as the likelihood that the individual does not have condition X (i.e., is not demonstrating negative response bias as evidenced by passing the TOMM) given a negative finding on test Y (i.e., scores below RBS cut-off) (Glaros An estimated base rate of the condition in question (in this case, invalid performance as evidenced by TOMM failure) is needed to calculate PPV and NPV. Given the heterogeneous sample in the present study, the selection of a base rate was challenging. As guidance, a recently published survey of the American Board of Clinical Neuropsychology members was reviewed (Mittenberg, Patton, Canock, & Condit, 2002) . Findings of the latter survey showed that base rates of probable malingering or symptom exaggeration among persons in litigation or seeking compensation status in several diagnostic groups were estimated to be relatively high: mild head injury 41%; fibromyalgia 39%; neurotoxic disorders 29%; electrical injury 26%; depressive disorders 16%, and anxiety disorders 14%. A decision was made to use the highest estimated base rate of malingering/symptom exaggeration found in that study (41%) for the following reasons: (1) approximately 26% of our sample reported mild head injury, (2) a number of individuals in our sample were suspected of malingering either by referring clinicians or chart review (i.e., severe symptom complaints in the absence of documented neurological problems), and, (3) in the veteran population, monetary gain is possible if (a) the veteran can show that his or her injury/illness was either caused or exacerbated by service and/or (b) the veteran served during a time of war, has limited income, and is deemed "permanently and totally disabled" (Veterans Benefits Administration, 2006).
Results
Group differences (as shown by t-tests and effect sizes) and Pearson correlations
Results of the t-tests showed that, of all the MMPI-2 validity tests evaluated (RBS F, Fb, Fp, FBS, Fptsd, and HHI), significant differences between the group who passed the TOMM (N = 24) and the group who failed the TOMM (N = 22) were only shown for the RBS, Fb, and the HHI ( Table 2 ). The effect sizes for these group differences are considered moderate to large (Lipsey, 1990 ) and were .98, .65 and .90, respectively. There were also trends for group differences on the F, Fp and Fptsd scales, p < .10. As expected, persons failing the TOMM scored higher, indicating more negative response bias, than those passing the TOMM on all validity indices. Results of Pearson correlations showed that the RBS, the Fptsd scale, and the HHI scale were all equally related to TOMM Trial 1; however, the RBS was most strongly related to the other trials of the TOMM (Table 3) .
Regression analyses
In nearly all of the regression analyses (see Table 4 ), RBS added significantly to the MMPI-2 scale evaluated (R 2 change = .10-.20, p < .01). The one exception was in the case of HHI, where there was only a trend for RBS to add significantly to the prediction of TOMM failure (R 2 change = .06, p = .069). As also found by Gervais et al. (2007) , review of beta weights for the analyses suggested that RBS provided the greatest relative contribution in predicting group membership. 
ROC, sensitivity, specificity, and predictive power analyses
As shown by the ROC analysis, the area under the curve of .750 (95% CI: .607-.893) suggests that the predictive information captured by the RBS score was reasonably good. Using the RBS cut-off score of 17, suggested by Gervais and colleagues (2007) , resulted in a somewhat low specificity of .92, but acceptable sensitivity of .50 (see Table 5 ). A more reasonable false positive rate (.04) was found when using a slightly higher cut-off score of 19 (specificity = .96). Using a cut-off of 19, only one participant passed the TOMM, but failed the RBS; that participant was diagnosed with depression and anxiety. At the cut-off of 19, the sensitivity of the RBS was considerably lower (sensitivity = .23) than Table 4 Hierarchical regression analyses: predicting TOMM performance (pass versus fail). at a cut-off score of 17 (sensitivity = .50), but was roughly similar to that found by Gervais and colleagues (2007) , who reported sensitivity values ranging from .25 to .29 when using a cut-off of 17 in their samples. As can be seen in Table 5 , using a cut-off of 19 on the RBS in the present study resulted in a PPV of .80 and a NPV of .64. See Table 6 for failure rates on the TOMM and RBS among the various study groups.
Discussion
The current study represents an extension and replication of a portion the original RBS validation study conducted by its developers, Gervais and colleagues (2007) . As in the original study, the current study employed a retrospective chart review of clinical patients who completed both the TOMM and the MMPI-2. The present study extended that of the original in that, in addition to examining the relationship between the TOMM, RBS, and several other wellresearched MMPI-2 validity scales (i.e., F, Fb, Fp, and FBS), it also included the recently developed Fptsd and HHI MMPI-2 validity scales. Findings of the current study provide evidence for the superiority of the RBS and, to some extent, the HHI over other MMPI-2 validity scales in predicting symptom validity test failure within an outpatient VA medical center population.
When MMPI-2 validity scale scores were compared between the groups who failed versus passed the TOMM, only the RBS, Fb, and HHI were significantly different between groups. There were also trends for significant differences in group means on F, Fp, and Fptsd. As expected, the group who failed the TOMM scored more highly than the group who passed the TOMM on each MMPI-2 validity measure. The RBS demonstrated the largest effect size (d = .98) between groups and was most consistently correlated with performances on the various trials of the TOMM. The latter is, perhaps, not surprising, considering that the RBS was designed to detect cognitive malingering, whereas the other MMPI-2 validity scales were developed to be sensitive to psychiatric/somatic malingering.
Regression analyses showed the RBS incrementally contributed to each MMPI-2 validity scale in predicting TOMM performance, with the exception of HHI, where there was only a trend for a significant contribution. In no case, did the addition of an MMPI-2 validity scale incrementally contribute to the RBS in predicting TOMM performance. ROC analysis suggested that a cut-off of 19 minimized false positives (specificity = .96) while retaining a reasonable sensitivity of .23, which is fairly typical in the practice of symptom validity testing. These data, suggest that, in terms of positive predictive value (PPV), using a RBS cut-off of 19, a clinician would have an 80% probability of being correct in suspecting a patient of invalid presentation given a positive finding on the RBS. In terms of negative predictive value (NPV), the same clinician would have a 64% probability of being correct in not suspecting a patient of possible invalid presentation given negative findings on the RBS. Thus, the results of the current study confirm the clinical utility of the RBS and suggest that, particularly if the MMPI-2 is an existing part of the neuropsychological assessment, examination of RBS scores is an efficient means of detecting symptom complaints that may be reflective of cognitive response bias.
Future research may address the possibility that some of the individuals who exceed the RBS cut-off score but who pass the TOMM (RBS "false positive" cases) actually represent persons who are truly demonstrating negative response bias but are not detected by the TOMM. This is a distinct possibility because, although the TOMM has been shown to have excellent specificity, correctly identifying 99.7% of non-malingerers, its sensitivity is only estimated to be adequate, correctly identifying only 34.3% of malingerers (Gervais, Rohling, Green, & Ford, 2004) . If the number of false positive cases is, indeed, overestimated in the current study, then the PPV and NPV of the RBS are likely to be considerably higher than estimated.
Although the TOMM was used to classify individuals as invalidly responding in the present study, it should be emphasized that the diagnosis of invalid presentation, especially if malingering is in question, is a clinical judgment that cannot be made on the results of one test alone, but must be made in consideration of other psychometric, behavioral, and collateral data (see Slick et al., 1999) . We are in agreement with Slick and colleagues that the routine use of at least two well-validated symptom validity tests should be a core element of neuropsychological assessment of individuals for whom secondary gain may be a factor. It seems clear that the use of two or more symptom validity tests will increase the examiner's ability to detect poor effort. However, it should be noted that the increase in sensitivity associated with the use multiple symptom validity tests comes with the concomitant increase in the potential for false positive errors. To minimize the potential for these false positive errors to contribute to the provision of incorrect diagnoses, each clinical case should be considered carefully and thoroughly, using not only psychometric, but also behavioral and collateral data when available.
We suggest that users of the RBS familiarize themselves with the original development and validation article written by Gervais et al. (2007) , as it provides guidelines for the interpretation of various combinations of RBS elevations and cognitive symptom validity test performance. Future research should continue to investigate the interrelationships among and diagnostic accuracy of cognitive symptom validity tests and MMPI-2 validity scales. Whereas the current findings suggest that the RBS is superior to the other MMPI-2 validity scales examined in detecting cognitive malingering, it is likely that some, if not all, of the other validity scales are superior to the RBS in detecting psychiatric/somatic malingering, as they were designed to do.
Future research may also address the applicability of these findings to various patient populations. In the present study, participants were either suspected of malingering prior to testing and/or were in a diagnostic group that is estimated to have a high base rate of malingering. Thus, the results of this study may not be representative of those that may be found in the general population. An attempt was made to compensate for the bias in our sample by using a high base rate of malingering when calculating the PPVs and NPVs of the RBS. However, statistically speaking, it is always true that PPVs will increase and NPVs will decrease with an increase in the base rate. As such, it may be that, in the general population, where the base rate of malingering is likely much lower, the RBS would demonstrate lower positive predictive power and higher negative predictive power.
